TLR4 Cancer Research Results

TLR4, Toll-like receptor 4: Click to Expand ⟱
Source:
Type:
Also called CD284 (cluster of differentiation 284)
A key activator of the innate immune response and plays a central role in the fight against bacterial infections.
Accumulating evidences demonstrated that the activation of TLR4 in tumor microenvironment can not only boost the anti-tumor immunity but also give rise to immune surveillance and tumor progression. "double-edged sword” role of TLR4 activation


Scientific Papers found: Click to Expand⟱
6195- Cuc,    Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends
- Review, Var, NA
TumCG↓, inhibition of tumor cell growth via induction of apoptosis, cell-cycle arrest, anti-metastasis and anti-angiogenesis are major promising chemo-preventive actions of cucurbitacins.
Apoptosis↑,
TumCCA↑,
TumMeta↓,
angioG↓,
chemoPv↑,
BioAv↓, CuB has been studied to be ~10% with plasma concentration ranging from 4.85 to 7.81 μg/L after 30 mins of oral dosing.
Half-Life↝, Studies have shown that they reach highest plasma concentration within 1.75 h and an elimination half-life of ~2.5 h.
cycD1/CCND1↓, decreased Cyclin D1 and Cyclin E1 levels.
cycE/CCNE↓,
Casp3↑, CRC cell lines underwent in vitro cell death when exposed to CuB, which was accompanied by caspase-3 and cleaved PARP
cl‑PARP↑,
JNK↑, (TNBC), cucurbitacin E strongly boosted JNK activation while considerably decreasing AKT and ERK activation in MDA-MB-468 cells.
Akt↓,
ERK↓,
survivin↓, also significantly decreased expression of Cyclin D1, Survivin, XIAP, Bcl2 and Mcl-1
XIAP↓,
Bcl-2↓,
Mcl-1↓,
ROS↑, In the pancreatic cancer cell line Capan-1, CuD induced cell-cycle arrest and death via the ROS/p38 pathway [43
NRF2↓, Recent studies have shown that CuIIb and cucurbitacin B induced apoptosis in cervical cancer cell lines by Nrf2 inhibition,
FAK↓, It successfully inhibited angiogenesis by targeting the FAK/MMP-9 signaling axis
MMP9↓,
VEGF↓, suppressed angiogenesis by downregulating the expression of HIF-1 targets, VEGF, VEGFR2 phosphorylation and erythropoietin
VEGFR2↓,
*NF-kB↓, Dietary cucurbitacin E has been shown to reduce inflammation and immunosuppression by downregulating the NF-κB signaling pathway
TLR4↝, Cucurbitacin B was observed to directly bind to toll-like receptor 4 (TLR4) and activate NLRP3 inflammasome, which further ultimately executed pyroptosis in A549 cells.
NLRP3↑,
Pyro↑,
GSH↓, It was observed that treatment with CuI and doxorubicin decreased glutathione (GSH) levels, enhancing cytotoxicity in tumors.


Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

GSH↓, 1,   NRF2↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics

XIAP↓, 1,  

Cell Death

Akt↓, 1,   Apoptosis↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   JNK↑, 1,   Mcl-1↓, 1,   Pyro↑, 1,   survivin↓, 1,  

DNA Damage & Repair

cl‑PARP↑, 1,  

Cell Cycle & Senescence

cycD1/CCND1↓, 1,   cycE/CCNE↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State

ERK↓, 1,   TumCG↓, 1,  

Migration

FAK↓, 1,   MMP9↓, 1,   TumMeta↓, 1,  

Angiogenesis & Vasculature

angioG↓, 1,   VEGF↓, 1,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling

TLR4↝, 1,  

Protein Aggregation

NLRP3↑, 1,  

Drug Metabolism & Resistance

BioAv↓, 1,   Half-Life↝, 1,  

Functional Outcomes

chemoPv↑, 1,  
Total Targets: 29

Pathway results for Effect on Normal Cells:


Immune & Inflammatory Signaling

NF-kB↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: TLR4, Toll-like receptor 4
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:559  State#:%  Dir#:4
wNotes=on sortOrder:rid,rpid

 

Home Page